Servier and BioCurate to collaborate on new drug discoveries
05 Aug 2019
French pharmaceutical company Servier Group, through its Australian
subsidiary, and Australia’s BioCurate
will share commercial and scientific expertise to accelerate the discovery
of new therapeutics and drugs.
The two companies have signed a memorandum of understanding under which
they will work together to advise on and assess new therapeutic candidates
arising from BioCurate’s academic partners.
BioCurate is a joint venture company of Monash University and The
University of Melbourne, with support from the Victorian Government. The
company engages with industry and investors to ensure projects receive
expert advice and assessment throughout the drug discovery process, with
the aim of increasing the number of investment-ready projects.
Servier is one of the first pharmaceutical companies to sign an agreement
with BioCurate to share expertise and accelerate discoveries of new drugs.
Servier has been operating in Australia since 1979, and opened an
International Centre for Theraupetic Research in Melbourne in 1999, its
first outside of Europe.
‘We are excited by the opportunity to create synergies between Servier’s
scientific expertise and capabilities and BioCurate’s know-how in improving
the quality of early-stage research for a successful translation into
therapeutic solutions for the benefit of patients,’
Pedro Crisanto, Director Servier International Centre for Therapeutic
Research Australia & New Zealand.
‘Australia has ranked fifth in the Scientific American Worldwide scorecard
three years running. Alongside BioCurate, Servier aims to translate this
exciting science into improved health outcomes for patients around the
BioCurate’s location in the
Melbourne Biomedical Precinct
– a cluster of hospitals, research institutes, and biotech organisations –
provides Servier with easy access to a thriving, world-class biomedical
Headquartered in Suresnes, France, Servier is a pharmaceutical company with
operations in 149 countries. It reinvests 25% of its income into research